Table 4.
Multiple-regression analysis of clinical trial publication characteristics
| No. (%) of Articles (n = 23) | Unadjusted Model Coefficient (SE) | t Value | P value | Consort Coefficients (SE) | Consort Standardized Coefficients | t Value | P value | |
|---|---|---|---|---|---|---|---|---|
| Type of intervention | ||||||||
| Device | 17 (9.5) | 1 (Ref) | 1 (Ref) | – | 1 (Ref) | 1 (Ref) | – | – |
| Drug | 78 (43.6) | 3.23 (4.0) | 0.79 | 0.429 | 2.48 (3.59) | 0.08 | 0.69 | 0.491 |
| Surgical | 34 (19.0) | −7.35 (4.53) | −1.62 | 0.107 | −5.59 (4.01) | −0.14 | −1.39 | 0.165 |
| Combo/other | 50 (27.9) | 4.66 (4.28) | 1.09 | 0.278 | 3.02 (3.75) | 0.09 | 0.81 | 0.421 |
| Publication year | ||||||||
| Before 2010 | 112 (62.6) | 1 (Ref) | 1 (Ref) | – | 1 (Ref) | 1 (Ref) | – | – |
| After 2010 | 67 (37.4) | 5.9 (0.02) | 2.46 | 0.015 | 5.61 (2.21) | 0.17 | 2.54 | 0.012 |
| Funding | ||||||||
| No funding received | 13 (7.3) | 1 (Ref) | 1 (Ref) | – | 1 (Ref) | 1 (Ref) | – | – |
| No funding statement | 64 (35.8) | 0.67 (4.23) | 0.16 | 0.875 | −2.81 (4.11) | −0.09 | −0.68 | 0.495 |
| Industry/private | 44 (24.6) | 15.02 (4.39) | 3.42 | 0.001 | 11.78 (4.28) | 0.32 | 2.75 | 0.007 |
| Other | 58 (32.4) | 16.34 (4.27) | 3.83 | 0 | 11.66 (4.35) | 0.35 | 2.68 | 0.008 |
| COI statement | ||||||||
| No | 87 (48.6) | 1 (Ref) | 1 (Ref) | – | 1 (Ref) | 1 (Ref) | – | – |
| Yes | 92 (51.40) | 6.81 (2.30) | 2.95 | 0.004 | 5.06 (2.12) | 0.16 | 2.39 | 0.018 |
COI, conflict of interest; CONSORT, Consolidated Standards of Reporting Trials.
CONSORT percentages were regressed on the type of intervention, publication year, and the presence of funding disclosures and conflict of interest statements, to evaluate whether the coded study characteristics accounted for variance in CONSORT scores.